Form 4: Recursion Pharmaceuticals Director Receives Significant Equity Compensation Grant

Recursion Pharmaceuticals, Inc. Director Zavain Dar was granted 22,016 restricted stock units and options to purchase 44,031 shares of Class A Common Stock as part of the company's compensation policy.

Summary

• Zavain Dar, a Director at Recursion Pharmaceuticals, Inc. (RXRX), received a grant of equity compensation on June 18, 2025.
• The grant included 22,016 shares of Class A Common Stock in the form of restricted stock units (RSUs), granted at a price of $0.
• Additionally, Mr. Dar was granted stock options to purchase 44,031 shares of Class A Common Stock at an exercise price of $5.11 per share, also granted at a price of $0.
• Both the RSUs and stock options were granted pursuant to the Issuer's Outside Director Compensation Policy.
• The restricted stock units and stock options are set to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on Mr. Dar's continued service to the Issuer.
• The stock options have an expiration date of June 18, 2035.
• Following these transactions, Mr. Dar directly beneficially owns 132,893 shares of Class A Common Stock and 44,031 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a standard equity compensation grant to a director, which is generally a positive sign of alignment and retention, but not indicative of extraordinary financial performance or strategic shifts. It's a routine, expected event.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of shareholders, as vesting is tied to continued service and future stock performance.
• The compensation package demonstrates the company's commitment to retaining key leadership through equity incentives.

Risks

• Vesting of the granted equity is subject to the reporting person's continued service to the Issuer, meaning the benefits are contingent on ongoing employment or board membership.

Future Outlook

The vesting schedule for the granted equity compensation extends to June 2026, indicating a future alignment of the director's incentives with the company's long-term performance and continued service.

Management Comments

• The filing indicates that the grant was automatically made pursuant to the Issuer's Outside Director Compensation Policy, reflecting a standard compensation practice.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, where equity incentives are a standard component of executive and director compensation packages to attract and retain talent and align interests with long-term growth.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to outside directors is a common practice in the biotechnology and pharmaceutical industries, aligning with compensation strategies seen at comparable companies.
• While specific compensation values vary, the structure of equity-based incentives tied to continued service is standard for attracting and retaining experienced board members in high-growth, research-intensive sectors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders through equity ownership, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• Vesting of restricted stock units and stock options on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Zavain Dar, Biotechnology, Pharmaceuticals